Fertility Disorders Clinical Trial
— FERTI-EMBOLOfficial title:
Uterine Artery Embolization For Uterine Pathology: What Impact On Fertility?
Uterine leiomyomas (or fibroids) are a common disease (30% of women over 35 years of age) in women of childbearing age and can cause various symptoms such as menometrorrhagia, dysmenorrhoea, pelvic pain and heaviness, and infertility. Uterine artery embolisation, first used in France in 1990, is a safe, effective and less invasive therapeutic technique than surgical treatment (myomectomy or hysterectomy), particularly in the case of numerous and large fibroids. This technique is validated by the French National College of Gynaecologists-Obstetricians (CNGOF) as an alternative treatment for women who do not wish to become pregnant (grade A recommendation), but at present there is little reliable data concerning fertility, the occurrence of pregnancy and the obstetrical prognosis after uterine artery embolisation for fibroids. A recent systematic review of the literature with meta-analysis published very recently showed that 40.5% of patients with a desire for pregnancy were able to become pregnant after embolisation (CI: 33.3%-48.2%) but that the rates of miscarriage, obstetric complications and low birth weight were not negligible (respectively 33.5% (95% CI: 26.3-41%), 25.4% (95% CI = 13-40.2%) and 10% (95% CI = 6.2-14.6%) (Ghanaati et al. 2020). In France, uterine artery embolisation is performed in more than thirty centres in women who have completed their parental project. On the other hand, in the absence of consistent literature, it is performed in patients of childbearing age, when it represents the only acceptable alternative or in the event of contraindication or refusal of surgery by the patient. To our knowledge, there is no large-scale French study to date on the impact of embolisation on fertility and pregnancy outcomes. The aim of this study is to compile a retrospective database of all cases of uterine artery embolisation for uterine pathology performed at the Georges-Pompidou European Hospital (HEGP) since 2007 and to assess the impact of embolisation on fertility in patients of childbearing age.
Status | Recruiting |
Enrollment | 833 |
Est. completion date | November 2023 |
Est. primary completion date | November 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Women = 18 years, = 45 years at the time of their embolisation - Uterine pathology responsible for disabling symptoms: uterine leiomyomas with no limitations in size, number or location, adenomyosis - Having had a uterine artery embolisation between 2007 and September 2020 - Minimum delay of one year after embolisation - Information and no opposition from patients Exclusion Criteria: - Women < 18 years and > 45 years at the time of embolisation - Uterine artery embolisation for delivery haemorrhage - Patients under court protection, guardianship or curatorship - Refusal to participate in this research |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Européen Georges Pompidou | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | Collège National des Gynécologues et Obstétriciens Français, Gedeon Richter France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of live births after embolisation | Rate of live births after embolisation (percentage) | one year | |
Secondary | Obstetrical outcomes after embolisation | Pregnancy rate (percentage) ;
Miscarriage rate (percentage) ; Assisted reproduction rate; Obstetric complication rates (haemorrhage, caesarean section, prematurity, pre-eclampsia, placental disorders) |
one year | |
Secondary | Effectiveness and safety of embolisation | Complication rate of embolisation (percentage)
Post-embolisation myomectomy and hysterectomy rates (percentage) |
one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05634850 -
Evaluating the Usability of the Product Kinder System Trial, Home Based Hormone for In-Vitro Fertilization (IVF) Monitoring System.
|
||
Completed |
NCT03803228 -
Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders
|
Phase 3 | |
Active, not recruiting |
NCT06053827 -
Natural Frozen Embryo Transfer (FET) vs Substituted Frozen Embryo Transfer (FET)
|
||
Recruiting |
NCT03480412 -
Second Step Protocol in Poor Ovarian Responder (POR)
|
||
Not yet recruiting |
NCT04604054 -
The Effect of Granulocyte Colony Stimulating Factor Versus Human Chorionic Gonadotropin in Females With a History of RIF
|
N/A | |
Not yet recruiting |
NCT04606082 -
Human Chorionic Gonadotropin Versus Granulocyte Colony Stimulating Factor in Increasing Pregnancy Rate in ICSI
|
N/A | |
Not yet recruiting |
NCT04589793 -
COaching Lifestyle Intervention for FErtility
|
N/A | |
Completed |
NCT06441409 -
Serum Ferritin Levels and Metabolic Dysfunction Associated Steatotic Liver Disease
|
N/A | |
Completed |
NCT03846544 -
Double Pick up in Poor Prognosis Women
|
Phase 4 | |
Completed |
NCT04141436 -
Hypnofertility for Women Undergoing In Vitro Fertilization (HWUIVF)
|
N/A | |
Completed |
NCT03161873 -
Cycle and Pregnancy Monitoring With Wearable Sensor Technology (AVA)
|
||
Completed |
NCT03007043 -
Genetic Variation in Gonadotropin and Gonadotropin Receptor Genes and Suboptimal Response
|
||
Completed |
NCT04133402 -
Fertility After Intrauterine Tamponing Balloon: Where Are we
|
||
Active, not recruiting |
NCT06128395 -
ASA 81 mg vs 162 mg During Frozen Embryo Transfer (FET)
|
||
Recruiting |
NCT05807256 -
Medically Assisted Fertilization Techniques in Systemic Immunoreumatologic Diseases
|
||
Completed |
NCT03908697 -
Quantum Natural Family Planning Pilot
|
N/A | |
Completed |
NCT04908774 -
Effects of a Fasting Mimicking Diet on Sperm Quality
|
N/A | |
Recruiting |
NCT05205733 -
Expanding Fertility Care to Poor and Low Resourced Settings Study
|
N/A | |
Active, not recruiting |
NCT03085212 -
Strategies for Pregnancy Achievement
|
N/A | |
Completed |
NCT01388907 -
Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery
|
Phase 4 |